adenine has been researched along with Leucocythaemia in 41 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "After Phase I studies of benzisoquinolinedione (amonafide) in solid tumors identified myelosuppression as the dose-limiting toxicity, we conducted a Phase I study in patients with relapsed or refractory acute leukemia to define the optimal dose." | 9.07 | Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. ( Benvenuto, JA; Beran, M; Estey, E; Felder, TB; Keating, M; O'Brien, S, 1991) |
| "After Phase I studies of benzisoquinolinedione (amonafide) in solid tumors identified myelosuppression as the dose-limiting toxicity, we conducted a Phase I study in patients with relapsed or refractory acute leukemia to define the optimal dose." | 5.07 | Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. ( Benvenuto, JA; Beran, M; Estey, E; Felder, TB; Keating, M; O'Brien, S, 1991) |
| "Certain D-arabinosyl nucleosides, notably arabinosyl cytosine (araC) and arabinosyl adenine (araA), are useful in the treatment of certain leukemias and some DNA virus infections, respectively." | 4.75 | The mechanisms of lethal action of arabinosyl cytosine (araC) and arabinosyl adenine (araA). ( Cohen, SS, 1977) |
| " A simple analytical method using high-performance LC/electrospray ionization-tandem mass spectrometry has been developed and validated for simultaneous quantification of BCR-ABL and Bruton's TKIs used for chronic leukemia (imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib) in human plasma." | 4.02 | High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma. ( Fukuhara, N; Hirasawa, T; Kikuchi, M; Maekawa, M; Mano, N; Ogura, J; Onishi, Y; Onodera, K; Sato, T; Sato, Y; Shigeta, K; Takasaki, S, 2021) |
| " Here side effects of ibrutinib have been summarized and important considerations in the management of these adverse events have been reviewed." | 2.61 | Management of adverse effects/toxicity of ibrutinib. ( Paydas, S, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (60.98) | 18.7374 |
| 1990's | 2 (4.88) | 18.2507 |
| 2000's | 2 (4.88) | 29.6817 |
| 2010's | 8 (19.51) | 24.3611 |
| 2020's | 4 (9.76) | 2.80 |
| Authors | Studies |
|---|---|
| Bon, C | 1 |
| Barbachowska, M | 1 |
| Djokovic, N | 1 |
| Ruzic, D | 1 |
| Si, Y | 1 |
| Soresinetti, L | 1 |
| Jallet, C | 1 |
| Tafit, A | 1 |
| Halby, L | 1 |
| Nikolic, K | 1 |
| Arimondo, PB | 1 |
| Hu, EY | 1 |
| Blachly, JS | 1 |
| Saygin, C | 1 |
| Ozer, HG | 1 |
| Workman, SE | 1 |
| Lozanski, A | 1 |
| Doong, TJ | 1 |
| Chiang, CL | 1 |
| Bhat, S | 1 |
| Rogers, KA | 1 |
| Woyach, JA | 2 |
| Coombes, KR | 1 |
| Jones, D | 1 |
| Muthusamy, N | 2 |
| Lozanski, G | 1 |
| Byrd, JC | 2 |
| Hirasawa, T | 1 |
| Kikuchi, M | 1 |
| Shigeta, K | 1 |
| Takasaki, S | 1 |
| Sato, Y | 1 |
| Sato, T | 1 |
| Ogura, J | 1 |
| Onodera, K | 1 |
| Fukuhara, N | 1 |
| Onishi, Y | 1 |
| Maekawa, M | 1 |
| Mano, N | 1 |
| Feldman, RC | 1 |
| Hyman, DA | 1 |
| Price, WN | 1 |
| Ratain, MJ | 1 |
| Paydas, S | 1 |
| Yun, SM | 1 |
| Jung, JH | 1 |
| Jeong, SJ | 1 |
| Sohn, EJ | 1 |
| Kim, B | 1 |
| Kim, SH | 1 |
| Dubovsky, JA | 1 |
| Beckwith, KA | 1 |
| Natarajan, G | 1 |
| Jaglowski, S | 1 |
| Zhong, Y | 1 |
| Hessler, JD | 1 |
| Liu, TM | 1 |
| Chang, BY | 1 |
| Larkin, KM | 1 |
| Stefanovski, MR | 1 |
| Chappell, DL | 1 |
| Frissora, FW | 1 |
| Smith, LL | 1 |
| Smucker, KA | 1 |
| Flynn, JM | 1 |
| Jones, JA | 1 |
| Andritsos, LA | 1 |
| Maddocks, K | 1 |
| Lehman, AM | 1 |
| Furman, R | 1 |
| Sharman, J | 1 |
| Mishra, A | 1 |
| Caligiuri, MA | 1 |
| Satoskar, AR | 1 |
| Buggy, JJ | 1 |
| Johnson, AJ | 1 |
| Pabst, C | 1 |
| Krosl, J | 1 |
| Fares, I | 1 |
| Boucher, G | 1 |
| Ruel, R | 1 |
| Marinier, A | 1 |
| Lemieux, S | 1 |
| Hébert, J | 1 |
| Sauvageau, G | 1 |
| Palmeira dos Santos, C | 1 |
| Pereira, GJ | 1 |
| Barbosa, CM | 1 |
| Jurkiewicz, A | 1 |
| Smaili, SS | 1 |
| Bincoletto, C | 1 |
| Kim, S | 1 |
| Hong, JH | 1 |
| Leong, DP | 1 |
| Caron, F | 1 |
| Hillis, C | 1 |
| Duan, A | 1 |
| Healey, JS | 1 |
| Fraser, G | 1 |
| Siegal, D | 1 |
| Yang, L | 1 |
| Yu, Y | 1 |
| Kang, R | 1 |
| Yang, M | 1 |
| Xie, M | 1 |
| Wang, Z | 1 |
| Tang, D | 1 |
| Zhao, M | 1 |
| Liu, L | 1 |
| Zhang, H | 1 |
| Cao, L | 1 |
| AUDRY, M | 1 |
| SCOTT, JL | 1 |
| VANDEVOORDE, JP | 1 |
| HANSEN, HJ | 1 |
| NADLER, SB | 1 |
| FURUKAWA, T | 1 |
| RIMAN, J | 1 |
| SAWITSKY, A | 1 |
| RUOHANI, J | 1 |
| LEVY, RN | 1 |
| EHRHART, H | 1 |
| SCHEFFEL, G | 1 |
| SATO, K | 1 |
| LEPAGE, GA | 1 |
| Sharif, FA | 1 |
| Yilmaz, Y | 1 |
| Zieske, A | 1 |
| Qumsiyeh, MB | 1 |
| Burchenal, JH | 1 |
| Dollinger, M | 1 |
| Butterbaugh, J | 1 |
| Stoll, D | 1 |
| Giner-Sorolla, A | 1 |
| Morita, Y | 1 |
| Siraganian, RP | 1 |
| Kefford, RF | 1 |
| Fox, RM | 1 |
| Barnes, MJ | 1 |
| Taylor, GA | 1 |
| Newell, DR | 1 |
| Cohen, SS | 1 |
| Fuska, J | 2 |
| Fuskova, A | 2 |
| Proksa, B | 1 |
| Kaneko, K | 1 |
| Fujimori, S | 1 |
| Kumakawa, T | 1 |
| Kamatani, N | 1 |
| Akaoka, I | 1 |
| O'Brien, S | 1 |
| Benvenuto, JA | 1 |
| Estey, E | 1 |
| Beran, M | 1 |
| Felder, TB | 1 |
| Keating, M | 1 |
| Tsutani, H | 1 |
| Yoshimura, T | 1 |
| Uchida, M | 1 |
| Kamiya, K | 1 |
| Ueda, T | 1 |
| Nakamura, T | 1 |
| Weber, G | 1 |
| Jayaram, HN | 1 |
| Lapis, E | 1 |
| Natsumeda, Y | 1 |
| Yamada, Y | 1 |
| Yamaji, Y | 1 |
| Tricot, GJ | 1 |
| Hoffman, R | 1 |
| Huang, P | 1 |
| Plunkett, W | 1 |
| Wolberg, G | 1 |
| Zimmerman, TP | 1 |
| Ohlsson-Wilhelm, BM | 1 |
| Farley, BA | 1 |
| Rudolph, NS | 1 |
| Rowley, PT | 1 |
| Smith, CM | 1 |
| Fontenelle, LJ | 1 |
| Lalanne, M | 1 |
| Henderson, JF | 1 |
| Rosman, M | 2 |
| Williams, HE | 1 |
| Lee, MH | 1 |
| Creasey, WA | 1 |
| Sartorelli, AC | 1 |
| Wilmanns, W | 1 |
| Smith, JL | 1 |
| Omura, GA | 1 |
| Krakoff, IH | 1 |
| Balis, ME | 1 |
| Kano, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2019-04-11 | Terminated (stopped due to Insufficient accrual) | ||
| An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia[NCT01217749] | Phase 1/Phase 2 | 71 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia[NCT01105247] | Phase 1/Phase 2 | 133 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410] | 40 participants (Actual) | Observational [Patient Registry] | 2018-12-01 | Completed | |||
| A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia[NCT02056782] | Phase 1 | 12 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Ibrutinib Plus Rituximab | 0 |
Number of participants who had experienced at least one treatment emergent AE (NCT01217749)
Timeframe: From first dose of study treatment to within 30 days of last dose or until study closure
| Intervention | participants (Number) |
|---|---|
| Group 1 | 27 |
| Group 2 | 20 |
| Group 3 | 24 |
The primary endpoint for the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR), CR with incomplete blood count recovery (Cri), or partial response (PR), according to the guidelines from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL1) published in 2008 for CLL participants and International Working Group for non-Hodgkin's lymphoma (IWG NHL) 2007 criteria for SLL participants, with the modification that treatment-related lymphocytosis will not be considered progressive disease, as evaluated by the investigators. Assessment of disease is based on radiological exams, physical exam, hematological evaluations and, when appropriate, bone marrow results. (NCT01217749)
Timeframe: The median follow-up time on study for all treated participants is 12.5 (range 0.5-19.6) months
| Intervention | percentage of participants (Number) |
|---|---|
| Group 1 | 92.6 |
| Group 2 | 80.0 |
| Group 3 | 70.8 |
"Progressive disease for CLL (Hallek) is characterized by ≥1 of the following:~Appearance of any new lesion, eg lymph nodes (> 1.5 cm), de novo hepatomegaly or splenomegaly, or other organ infiltrates~Increase of ≥50%~in longest diameter of any previous site~in hepatomegaly or splenomegaly~in blood lymphocytes with ≥5x109/L B cells with enlarging lymph node, liver, or spleen~Progressive disease for B cell lymphoma (Cheson) is characterized by any new lesion or increase by ≥ 50% of previously involved sites from nadir:~Appearance of a new lesion(s) >1.5 cm in any axis, ≥ 50% increase in the SPD of >1 node, or ≥50% increase in longest diameter of a previously identified node >1 cm in short axis~Lesions PET+ if FDG-avid lymphoma or PET+ before therapy~50% increase from nadir in the SPD of any liver or spleen lesions~New or recurrent BM involvement~Increase of ≥50% in blood lymphocytes with ≥5x109/L B cells within enlarging lymph node, liver, or spleen" (NCT01217749)
Timeframe: From first dose of study treatment until disease progression, death, or until 12 months
| Intervention | percentage of event free participants (Mean) |
|---|---|
| Group 1 | 88.7 |
| Group 2 | 85.0 |
| Group 3 | 75.0 |
Number of dose-limiting toxicities observed in the first 6 participants enrolled in treatment Groups 1 and 2 (NCT01217749)
Timeframe: 56 days for Group 1 and 28 days for Group 2
| Intervention | participants who experienced DLT (Number) |
|---|---|
| Group 1 | 0 |
| Group 2 | 0 |
Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. (NCT01105247)
Timeframe: Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design.
| Intervention | (Number) |
|---|---|
| Food Effect Cohort | 1.65 |
Number of participants who had experienced at least one treatment emergent AEs. (NCT01105247)
Timeframe: From first dose to within 30 days of last dose of PCI-32765
| Intervention | Participants (Number) |
|---|---|
| PCI-32765 | 116 |
| Food Effect | 11 |
Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).
| Intervention | Percentage of Participants (Number) |
|---|---|
| Treatment Naive | 71 |
| Relapsed/ Refractory | 75.3 |
| Food Effect | 56.3 |
Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).
| Intervention | Percentage of Participants (Number) |
|---|---|
| Treatment Naive | 96.3 |
| Relapsed/ Refractory | 73.6 |
| Food- Effect | NA |
"A secondary endpoint of this study was to determine whether there was preliminary evidence of an effect of dociparstat on remission rate following cytarabine and idarubicin induction in acute myeloid leukemia (AML) patients, which included complete remission (CR) rate (with neutrophil and platelet count recovery) after the first induction cycle.~Morphologic CR was defined as absolute neutrophil count (ANC) >1000/μL, platelet count >100,000/μL, <5% bone marrow blasts, no Auer rods, and no evidence of extramedullary disease." (NCT02056782)
Timeframe: Day 1 to Day 35 (35 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Dociparstat | 11 |
A primary endpoint of this study was evidence of an effect of dociparstat on transfusion independent platelet recovery time. The time (days) to transfusion-independent platelet recovery will be defined as the number of days from the first day of chemotherapy until the first of 5 consecutive days with platelet counts values ≥ 20,000/μL and ≥ 50,000/μL without a platelet transfusion. (NCT02056782)
Timeframe: Day 1 to Day 35 (35 days)
| Intervention | days (Mean) | |
|---|---|---|
| Platelet count of ≥20,000/µL | Platelet count of ≥50,000/µL | |
| Dociparstat | 21.3 | 23.1 |
3 reviews available for adenine and Leucocythaemia
| Article | Year |
|---|---|
Management of adverse effects/toxicity of ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Atrial Fibrillation; Drug-Related Side Effects and Adv | 2019 |
The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Atrial Fibrillation; Humans; Incidence; Leuke | 2016 |
The mechanisms of lethal action of arabinosyl cytosine (araC) and arabinosyl adenine (araA).
Topics: Adenine; Adenosine Deaminase Inhibitors; Adenosine Monophosphate; Adenosine Triphosphate; Animals; A | 1977 |
2 trials available for adenine and Leucocythaemia
| Article | Year |
|---|---|
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur | 2013 |
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur | 2013 |
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur | 2013 |
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur | 2013 |
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur | 2013 |
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur | 2013 |
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur | 2013 |
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur | 2013 |
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Topics: Adenine; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Humans; Jur | 2013 |
Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adenine; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evalu | 1991 |
36 other studies available for adenine and Leucocythaemia
| Article | Year |
|---|---|
Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies.
Topics: Adenine; Antidotes; Histone-Lysine N-Methyltransferase; Humans; Leukemia; Molecular Docking Simulati | 2022 |
LC-FACSeq is a method for detecting rare clones in leukemia.
Topics: Adenine; Clonal Evolution; Clone Cells; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Mu | 2020 |
High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
Topics: Adenine; Aniline Compounds; Chromatography, Liquid; Dasatinib; Drug Monitoring; Female; High-Through | 2021 |
Negative innovation: when patents are bad for patients.
Topics: Adenine; Antineoplastic Agents; Humans; Leukemia; Lymphoma; Patents as Topic; Patient Harm; Piperidi | 2021 |
Tanshinone IIA induces autophagic cell death via activation of AMPK and ERK and inhibition of mTOR and p70 S6K in KBM-5 leukemia cells.
Topics: Abietanes; Adenine; AMP-Activated Protein Kinases; Autophagy; Cell Line, Tumor; Extracellular Signal | 2014 |
Identification of small molecules that support human leukemia stem cell activity ex vivo.
Topics: Adenine; Cell Culture Techniques; Culture Media, Serum-Free; Drug Screening Assays, Antitumor; Human | 2014 |
Comparative study of autophagy inhibition by 3MA and CQ on Cytarabine‑induced death of leukaemia cells.
Topics: Adenine; Antimalarials; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Synthesis and Biological Evaluation of 9-Deazaadenine 5'-Deoxy-6',6'-Difluoro-Carbocyclic C-Nucleoside Phosphonic Acid Derivatives.
Topics: Adenine; Animals; Anti-HIV Agents; Antineoplastic Agents; Cell Line, Tumor; Drug Design; HIV-1; Huma | 2015 |
Up-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells.
Topics: Adenine; Autophagy; Blotting, Western; Cell Proliferation; Cells, Cultured; Child; Drug Resistance, | 2012 |
[Action of adenine on leukopoiesis].
Topics: Adenine; Humans; Leukemia; Leukopoiesis | 1960 |
Human leukocyte metabolism in vitro. I. Incorporation of adenine-8-C-14 and formate-C-14 into the nucleic acids of leukemic leukocytes.
Topics: Adenine; Formates; Humans; In Vitro Techniques; Leukemia; Leukocytes; Nucleic Acids | 1962 |
METABOLISM OF LEUKEMIC CELLS IN CULTURE; AZASERINE INHIBITION OF J-128 (OSGOOD).
Topics: Adenine; Azaserine; Carbon Isotopes; Glycine; Guanine; Hypoxanthines; Imidazoles; Leukemia; Metaboli | 1964 |
[STUDIES ON TISSUE CULTURE OF LEUKEMIC CELLS IN CHILDREN. 1. CONSIDERATIONS ON THE BASIC CONDITIONS FOR THE 1ST CULTURE].
Topics: Adenine; Adolescent; Child; Corrinoids; Hematinics; Humans; Immune Sera; Infant; Leucovorin; Leukemi | 1964 |
EXPERIMENTAL VIRAL LEUKAEMIA AS A RHYTHMIC GROWTH PROCESS. II. SYSTEMATIC FLUCTUATION OF THE ADENOSINETRIPHOSPHATE (ATP) CONTENT AND CHANGES IN THE FREE ADENINE NUCLEOTIDE (ATP, ADP, AMP) POOL IN LEUKAEMIC CELLS DURING THE LEUKAEMIC PROCESS.
Topics: Adenine; Adenine Nucleotides; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate | 1964 |
DRUG FEVER PRODUCED BY SIX-MERCAPTOPURINE.
Topics: Adenine; Antineoplastic Agents; Drug Therapy; Fever; Hematocrit; Leukemia; Leukocyte Count; Mercapto | 1964 |
[STUDIES ON LEUKOCYTE METABOLISM. NICOTINAMIDE-ADENINE-DINUCLEOTIDE (NAD) CONTENT OF NORMAL AND LEUKEMIC LEUKOCYTES IN MAN. II].
Topics: Adenine; Blood Cell Count; Blood Chemical Analysis; Erythrocytes; Humans; Leukemia; Leukemia, Lympho | 1965 |
METABOLIC EFFECTS OF AN ANTIBIOTIC, NSC-51954, ON SUSCEPTIBLE AND RESISTANT TUMOR CELLS.
Topics: Adenine; Animals; Anti-Bacterial Agents; Carbon Isotopes; Carcinoma, Ehrlich Tumor; DNA; DNA, Neopla | 1965 |
Natural killer cell lymphoma/leukemia with homozygous loss of p27/kip1.
Topics: Adenine; Aged; Amino Acid Sequence; Base Sequence; Cyclin-Dependent Kinase Inhibitor p27; Cytogeneti | 2005 |
Studies of 6-N-hydroxylamino-9-beta-D-ribofuranosylpurine in mouse leukemia.
Topics: Adenine; Animals; Body Weight; Cytarabine; Drug Antagonism; Drug Synergism; Fluorouracil; Guanine; L | 1967 |
Inhibition of IgE-mediated histamine release from rat basophilic leukemia cells and rat mast cells by inhibitors of transmethylation.
Topics: Adenine; Adenosine; Animals; Basophils; Female; Histamine Release; Homocysteine; Immunoglobulin E; L | 1981 |
Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
Topics: Adenine; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Cell Survival; Cells, Cultured; Coform | 1983 |
Development of a whole cell assay to measure methotrexate-induced inhibition of thymidylate synthase and de novo purine synthesis in leukaemia cells.
Topics: Adenine; Antimetabolites, Antineoplastic; Child; Guanine; Humans; Inosine; Leukemia; Methotrexate; P | 2000 |
The in vitro-in vivo effect of antibiotic PSX-1 on lympholeukaemia L-5178.
Topics: Adenine; Animals; Antibiotics, Antineoplastic; Cells, Cultured; Leukemia; Male; Mice; Neoplasm Trans | 1976 |
New potential cytotoxic and antitumor substances I. In vitro effect of bikaverin and its derivatives on cells of certain tumors.
Topics: Adenine; Animals; Carcinoma, Ehrlich Tumor; Cells, Cultured; DNA, Neoplasm; In Vitro Techniques; Leu | 1975 |
Disturbance in the metabolism of 5'-methylthioadenosine and adenine in patients with neoplastic diseases, and in those with a deficiency in adenine phosphoribosyltransferase.
Topics: Adenine; Adenine Phosphoribosyltransferase; Adenosine; Adult; Aged; Deoxyadenosines; Female; Humans; | 1991 |
Purine nucleotide synthesis during terminal differentiation.
Topics: Adenine; Cell Differentiation; Cell Division; Dimethyl Sulfoxide; Glycine; Humans; Hypoxanthines; Le | 1989 |
Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.
Topics: Adenine; Aged; Allopurinol; Animals; Drug Evaluation; Female; Guanine; Guanosine Triphosphate; Human | 1988 |
Phosphorolytic cleavage of 2-fluoroadenine from 9-beta-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli. A pathway for 2-fluoro-ATP production.
Topics: Adenine; Adenosine; Adenosine Triphosphate; Animals; Binding, Competitive; Cell Line; Escherichia co | 1987 |
Effects of adenosine deaminase inhibitors on lymphocyte-mediated cytolysis.
Topics: Adenine; Adenosine; Adenosine Deaminase Inhibitors; Animals; Cell Line; Coformycin; Cytotoxicity, Im | 1985 |
Erythroid induction of K562 human leukemia cells: enhancement by purines.
Topics: Adenine; Cell Cycle; Cell Division; Cell Line; Drug Synergism; Guanine; Hemoglobins; Humans; Hypoxan | 1985 |
Inhibition of purine ribonucleotide and phosphoribosyl pyrophosphate synthesis by 6-cyclopentylthio-9-hydroxymethylpurine and structurally related compounds.
Topics: Adenine; Animals; Carbon Radioisotopes; Carcinoma, Ehrlich Tumor; Cell Line; Cells, Cultured; Cyclop | 1974 |
Leukocyte purine phosphoribosyltransferases in human leukemias sensitive and resistant to 6-thiopurines.
Topics: Adenine; Adolescent; Adult; Aged; Antimetabolites; Drug Resistance; Female; Guanine; Humans; Hypoxan | 1973 |
Mechanisms of resistance to 6-thiopurines in human leukemia.
Topics: Adenine; Alkaline Phosphatase; Drug Resistance; Guanine; Humans; Hypoxanthines; Leukemia; Leukemia, | 1974 |
Synthesis of purine nucleotides in human and leukemic cells. Interaction of 6-mercaptopurine and allopurinol.
Topics: Adenine; Allopurinol; Bone Marrow; Bone Marrow Cells; Carbon Radioisotopes; Cell-Free System; Chroma | 1973 |
IMP: and AMP:pyrophosphate phosphoribosyltransferase in leukemic and normal human leukocytes.
Topics: Adenine; Carbon Isotopes; Erythrocytes; Guanine; Humans; Hypoxanthines; In Vitro Techniques; Leukemi | 1971 |
[Nucleic acid metabolism of leukemic leukocytes. 2. The effect of 6-mercaptopurine on nucleic acid metabolism of leukemic leukocytes].
Topics: Adenine; Carbon Isotopes; Guanine; Humans; Hypoxanthines; Leukemia; Leukocytes; Mercaptopurine; Nucl | 1968 |